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INTRODUCTION 
In advanced stages of kidney failure Transplantation is the treatment of 
choice. Successful kidney transplant offers the potential for complete 
rehabilitation. Kidney transplantation is the definitive treatment of ESRD, 
treating all manifestations of chronic kidney disease. A successful kidney 
transplant improves the quality of life and reduces the mortality risk for most 
patients when compared with those on maintenance dialysis. Survival with 
kidney transplantation is superior to dialysis. 
 
Despite improvement in the short term patient and graft outcomes there 
has no major improvement in the long term outcome. The incidence of 
cardiovascular disease (CVD) is very high in patients with chronic kidney 
(CKD) disease and in kidney transplant recipients. Indeed, available evidence 
for these patients suggests that the 10-year cumulative risk of coronary heart 
disease is at least 20%, or roughly equivalent to the risk seen in patients with 
previous CVD.  
 
Recently, the National Kidney Foundation’s Kidney Disease Outcomes 
Quality Initiative (K/DOQI) published guidelines for the diagnosis and 
treatment of dyslipidemias in patients with CKD, including transplant 
patients. It was the conclusion of this Work Group that the National 
Cholesterol Education Program Guidelines are generally applicable to patients 
with CKD, but that there are significant differences in the approach and 
   
treatment of dyslipidemias in patients with CKD compared with the general 
population. 
   Evidence from the general population indicates that treatment of 
dyslipidemias reduces CVD. Dyslipidemias are very common in CKD and in 
transplant patients and evidence in kidney transplant patients suggests that 
judicious treatment can be safe and effective in improving dyslipidemias. 
However, until recently there have been no adequately powered, randomized, 
controlled trials examining the effects of dyslipidemia treatment on CVD in 
patients with CKD. 
 
 Cardiovascular disease is the most common cause of post transplant 
mortality and morbidity among long – term kidney transplant survivors. 
Patients with post transplantation coronary artery disease tend to be older 
males, diabetics with higher cholesterol levels, greater incidence of smoking 
and greater number of acute rejection episodes and as a consequence have 
received more cumulative doses of steroids. The prevalence of lipid 
abnormalities after kidney transplantation is very high.  
 
There is need for collaboration among the transplant centre, 
community nephrologists, and primary care physicians who are involved in 
the long term care of these patients to enhance the outcome. Prevention and 
early management of disease progression and addressing the cardiovascular 
   
complications, infections, and malignancies constitute the cornerstone of this 
collaborative effort to extend the lifespan and allograft function.  
 
  Grossly enlarged Cardio vascular disease risk among the transplant 
patients is due to combination of traditional and non-traditional risk factors. 
Traditional risk factors include male sex, old age, race, hypertension, diabetes 
mellitus, sedentary life style, obesity, hyperlipidemia, smoking and            
postmenopausal state. Hyperuricemia, hyperhomocysteinemia, 
hyperparathyroidism, proteinuria, systemic inflammation, calcium and 
phosphorus are the emerging non-traditional risk factors among the kidney 
transplant patients.  
 
 In the recent years there has been much progress made in the 
understanding the causes and management of the atherosclerotic lipid 
abnormalities   among the kidney transplant patients. 
 
   
AIMS AND OBJECTIVES 
 
1. To assess the nature of Lipid profile abnormalities prevalent among 
kidney transplant patients. 
 
2. To apply NKF recommendations on Dyslipidemia management. 
 
3. To critically analyse the data & to interpret its utility for the 
Therapeutic interventions. 
   
REVIEW OF LITERATURE 
 
 Chronic kidney disease becomes the global epidemic. Management of 
such a devastating disease is a highly complicated issue even among the well 
developed countries.  
 
Medical, ethical, psychological and socio-economic problems 
associated with chronic kidney disease is a large burden to the healthcare 
sector of the developing countries like India. 
 
Chronic kidney disease (CKD) is defined as at least 3 months of either:  
 
1. structural or functional abnormalities of the kidney that can lead to 
kidney failure; or  
 
2. GFR <60 mL/min/1.73m2. 
 
Causes of Chronic kidney disease includes primary or secondary 
glomerulonephritis, diabetic nephropathy, hypertensive nephrosclerosis, 
chronic pyelonephritis, analgesic nephropathy, obstructive uropathy, 
polycystic kidney disease, vesicoureteric reflux, renal tuberculosis and 
nephrocalcinosis.  
 
   
Stages of chronic kidney disease 
Stage Description GFR (mL/min/1.73m2)
1 Kidney damage with normal GFR > 90 
2 Kidney damage with mild reduction of 
GFR 
60 – 89 
3 Moderate reduction of GFR 30 – 59 
4 Severe reduction of GFR 15 – 29 
5 Kidney failure < 15 or dialysis 
 
ESRD patients at high risk for cardiovascular disease 
 Age above 65 
 Diabetes mellitus 
 MI/Myocardial dysfunction  
 History of Angina 
 Long duration ESRD 
They should be aggressively screened for inducible ischemia & myocardial 
dysfunction (Atleast by stress testing & ECHO) 
 
 Transplantation of the human kidney is frequently the most effective 
treatment of advanced chronic kidney failure. Worldwide, tens of thousands 
of such procedures have been performed. When azathioprine and prednisone 
were initially used as immunosuprressive drugs in the 1960s, the results with 
properly matched familial donors were superior to those with organs from 
   
cadaveric donors, namely, 75 to 90% compared with 50 to 60% graft survival 
rates at 1 year. During the 1970s and 1980s, the success rate at the 1-year for 
cadaveric transplant rose progressively. 
 
By the time cyclosporine was introduced in the early 1980s, cadaveric 
donor grafts had a 70% 1-year survival and reached the 82% level in the mid-
1990s and 88% by 1998. After the first year, graft survival curves show an 
exponential decline in numbers of functioning grafts from which a half-life 
(t1/2) in years is calculated; this has increased by 2 years since the 1980s.  
 
Mortality rates after transplantation are highest in the first year and are 
age-related: 2% for ages 18 to 34 years, 3% for ages 35 to 49 years, and 6.8% 
for ages over 50 to 60 years. These rates compare favorably to those in the 
chronic dialysis population, even after risk adjustments for age, diabetes, and 
cardiovascular status. Most grafts, however, succumb at varying rates to a 
chronic vascular and interstitial obliterative process termed chronic rejection.  
 
RECIPIENT SELECTION  
There are few absolute contraindications to kidney transplantation. The 
transplant procedure is relatively noninvasive, as the organ is placed in the 
inguinal fossa without entering the peritoneal cavity. Recipients without 
perioperative complications can often be discharged from the hospital in 
excellent condition within 5 days of the operation.  
 
   
Virtually all end-stage kidney disease (ESRD) patients who receive a 
transplant have a higher life expectancy than risk-matched patients who 
remain on dialysis. Even though diabetics or older candidates have a higher 
mortality rate than other transplant recipients, their survival is improved with 
transplantation compared to remaining on dialysis. This global benefit of 
transplantation as a treatment modality poses substantial ethical issues for 
policy makers, as the number of cadaveric kidneys available is far from 
sufficient to meet the current needs of the candidates. Waiting lists continue 
to grow, and the average wait time for a cadaver kidney is now >4 years in 
many locales. The current standard of care is that the candidate should have a 
life expectancy of >5 years to be put on a cadaver organ wait list. Even for 
living donation, the candidate should have >5 years of life expectancy. This is 
because the benefits of kidney transplantation over dialysis are only realized 
after a perioperative period in which the mortality is higher in transplanted 
patients than in dialysis patients with comparable risk profile.  
 
DONOR SELECTION  
Types of donor are living related donor, live unrelated donor and 
cadaveric graft.  Living related - offers the advantage of optimally timed 
surgical procedure, HLA halotype matching, and improved graft survival. 
Live unrelated donation –option which becomes common place. Consent and 
HLA halotpye matching is problematic. But comparable graft survival is 
possible with minimal mismatching. 
   
The living volunteer donors are usually family members selected to 
have at least partial compatibility for HLA antigens. They should be normal 
on physical examination and of the same major ABO blood group, because 
crossing major blood group barriers prejudices survival of the allograft. It is 
possible, however, to transplant a kidney of a type O donor into an A, B, or 
AB recipient. 
 
With the acceptance of concept of brain death in India an increasing 
numbers of cadaveric transplants are being performed. Cadaveric donors 
should be free of malignant neoplastic disease, hepatitis, and HIV because of 
possible transmission to the recipient.   
 
Selective renal arteriography should be performed on donors to rule 
out the presence of multiple or abnormal renal arteries, because the surgical 
procedure is difficult and the ischemic time of the transplanted kidney is long 
when vascular abnormalities exist. Transplant surgeons are now using a 
laparascopic method to isolate and remove the living donor kidney. This 
operation has the advantage of less evident surgical scars, and, because there 
is less tissue trauma, the laparoscopic donors have a substantially shorter 
hospital stay and less discomfort than those who have the traditional surgery. 
Increased risk of graft failure exists when the donor is elderly or has kidney 
failure and when the kidney has a prolonged period of ischemia and storage.  
 
   
Usually Hemodialysis done, before transplantation to ensure a 
relatively normal metabolic state in recipients. The recipient’s own kidneys 
are left undisturbed. In a transplant operation the donor kidney is placed in a 
extra peritoneal pouch in the iliac fossa of the recipient. The renal artery and 
vein are anastomosed to the recipient’s iliac vessels. The donor ureter is 
implanted into the bladder of the recipient.  
 
TISSUE TYPING AND CLINICAL IMMUNOGENETICS  
Donor HLA is matched with that of recipient. It is preferable to have a 
HLA identical donor. If such donor is not available halpo identical (half  
identical) could be done. Matching for antigens of the HLA major 
histocompatibility gene complex is an important criterion for selection of 
donors for kidney allografts. Each mammalian species has a single 
chromosomal region that encodes the strong, or major, transplantation 
antigens, and this region on the human sixth chromosome is called HLA.  
 
HLA antigens have been classically defined by serologic techniques, 
but methods to define specific nucleotide sequences in genomic DNA are 
increasingly being used.  
 
The Rh system is not expressed on graft tissue. About 5% of HLA-
identical kidney allografts are rejected, often within the first weeks after 
   
transplantation. These failures represent states of prior sensitization to non-
HLA antigens.  
 
Living Donors   
When first-degree relatives are donors, graft survival rates at 1 year are 
5 to 7% greater than those for cadaver grafts. The 5-year survival rates still 
favor the partially matched (3/6 HLA mismatched) family donor over a 
randomly selected cadaver donor.  
 
For both living and cadaveric donors, the 5-year outcomes are poor if 
there is a complete (6/6) HLA mismatch. In response to this increasing 
disparity between cadaver donor supply and patient demand, living unrelated 
volunteers, usually spouses or close friends, are being accepted as donors in 
increasing numbers. 
 
The survival rate of living unrelated kidney allografts is as good or 
better than that of perfectly HLA matched cadaver kidney transplants and 
comparable to that of kidneys from living relatives. This is likely to be a 
consequence both of short cold ischemia time and extra care taken to 
document that kidney function of the donor are optimal before proceeding 
with a living unrelated donation.  
Concern has been expressed regarding the potential risk to a volunteer 
kidney donor of premature kidney failure after several years of increased 
blood flow and hyperfiltration per nephron in the remaining kidney. There are 
   
a few reports of the development of hypertension, proteinuria, and even 
lesions of focal segmental sclerosis in donors under long-term follow-up. 
Difficulties in donors followed for 20 years are unusual, however, and it may 
be that having a single kidney becomes significant only when another 
condition, such as hypertension, is superimposed. It is also desirable to 
consider the risk of development of type 1 diabetes mellitus in a family 
member who is a potential donor to a diabetic kidney failure patient.  
 
Anti-insulin and anti-islet antibodies should be measured, and glucose 
tolerance tests should be performed in such donors to rule out a prediabetic 
state. It is now possible to remove cadaver kidneys and to maintain them for 
up to 48 h on cold pulsatile perfusion or simple flushing and cooling. This 
permits adequate time for typing, cross-matching, transportation, and 
selection problems to be solved. 
 
HLA Matching and Cadaveric Donors 
Now that pooled data on tens of thousands of cadaveric kidney 
transplants from all over the world are available, the HLA-matching effect 
can be clearly seen, especially in the long-term survival figures. There is an 
overall beneficial effect of HLA matching in cadaveric grafts. With increasing 
numbers of mismatches for cadaveric donors, the 5-year survival drops from 
68.2% to 55.3%.  
 
   
The survival rates at the 10-year mark are projected to range from 65 
(zero mismatches) to 34% (six mismatches). Kidneys from HLA-
incompatible unrelated or spousal donors do better than those from similarly 
mismatched cadaver donors, Nevertheless, when such a cadaveric donor is 
HLA-compatible, the benefit of matching can still be seen.  
 
CARDIOVASCULAR RISKS IN TRANSPLANT PATIENTS: 
The leading cause of post transplant death is CVD, responsible for 
30%-40% of deaths. Although death rates from CVD are lower than in 
dialysis patients, they still exceed those of the general population.  
 
Kasiske estimated the cumulative incidence of coronary heart disease, 
cerebrovascular disease, and peripheral vascular disease at 15 years post 
transplant to be 23%, 15%, and 15%, respectively. Many risk factors, such as 
diabetes mellitus, hypertension, hepatitis C virus antibodies (HCV), 
dyslipidemia, proteinuria, and serum creatinine levels, and 
hyperhomocysteinemia are overrepresented in Transplant Recipients.  
 
Of course, these risk factors usually arise many years before 
transplantation, indeed even before dialysis. Thus, reducing the risk of CVD – 
and indeed, of the other conditions discussed below – requires intervention 
when patients are either pre-dialysis or on dialysis. 
 
   
 Although the emphasis has traditionally been on the burden of 
coronary heart disease among kidney transplant patients, recent studies 
emphasize that the prevalence of cardiomyopathy (presenting clinically as 
congestive heart failure or as left ventricular enlargement on 
echocardiography) is significantly increased in these patients. 
 
1year graft survival HLA identical- 95% 1 MISMATCH – 90 TO 
95% COMPLETE MISMATCH – 75 TO 80%. Average half –life of 
cadaveric grafts is 8yrs. For HLA identical living related donor grafts- 20 yrs.  
  
Long-term cadaveric and living donor kidney allograft survival 
continues to improve. This reflects many factors, including lower rates of 
acute rejection (mainly due to better immunosuppressive regimens), better 
antimicrobial prophylaxis, and probably, improvements in general medical 
and surgical care.  
 
Causes of allograft loss after year one 
 Patient death 50% 
 Chronic allograft nephropathy 35% 
 Acute rejection/Non compliance 10% 
 Recurrent disease 4% 
Patient death 
No 1 cause is cardiovascular disease followed by infection and 
malignancy. 
   
Measures to improve kidney allograft survival 
1. Increase Living donor donation – both related & non related. 
2. Preemptive transplantation. 
3. Increase donation from younger and previously healthy cadaveric 
donors. 
4. Zero HLA Mismatching 
5. Better donor preparation, improved organ preservation, faster 
matching & transplantation, reduced cold Ischemia time. 
6. ACE inhibitors and Angiotensin receptor blockers usage. 
7. Nephron dosing (Matching of donor & recipient age sex, and BMI) 
8. High quality general medical care. Aggressive control of 
Dyslipidemia & Hypertension. 
   
Effect of HLA-A, -B, -DR Mismatching on Kidney Graft Survival 
 
Degree of Donor 
mismatch 
1-year survival % 5-year survival % 
Cadaver donor (all)   
0/6-HLA mismatch   
3/6-HLA mismatch  
6/6-HLA mismatch  
 
Living related donor (all) 
0/6-HLA mismatch   
3/6-HLA mismatch  
6/6-HLA mismatch   
 
Living unrelated donor 
89.2 
91.3 
90.1 
85.2 
 
94.7 
96.7 
94.3 
92.7 
 
95.3 
61.3 
68.2 
60.8 
55.3 
 
76.0 
87.0 
73.2 
57.7 
 
77.4 
 
   
        
Presensitization   
A positive cross match of recipient serum with donor T lymphocytes 
representing anti-HLA class I is usually predictive of an acute vasculitic event 
termed hyperacute rejection. Patients with anti-HLA antibodies can be safely 
transplanted if careful cross-matching of donor blood lymphocytes with 
recipient serum is performed. Patients sustained by dialysis often show 
fluctuating antibody titers and specificity patterns. At the time of assignment 
of a cadaveric kidney, cross matches are performed with at least a current 
serum.  
   
Techniques for cross-matching are not universally standardized; 
however, at least two techniques are employed in most laboratories. The 
minimal purpose for the cross match is avoidance of hyperacute rejection 
mediated by recipient antibodies to donor HLA class I antigens. Sensitive 
tests, such as the use of flow cytometry, can be useful for avoidance of 
accelerated, and often untreatable, early graft rejection in patients receiving 
second or third transplants.  
 
Donor T lymphocytes, which express only class I antigens, are used as 
targets for detection of anti-class I (HLA-A and -B) antibodies. Preformed 
anti-class II (HLA-DR) antibodies against the donor carry a higher risk of 
graft loss as well, particularly in recipients who have suffered early loss of a 
prior kidney transplant. B lymphocytes expressing both class I and class II 
antigens are used in these assays. 
 
Drugs for Immunosuppression 
Azathioprine, an analogue of mercaptopurine, was for two decades the 
keystone to immunosuppressive therapy in humans. This agent can inhibit 
synthesis of DNA, RNA, or both. Because cell division and proliferation are a 
necessary part of the immune response to antigenic stimulation, suppression 
by this agent may be mediated by the inhibition of mitosis of 
immunologically competent lymphoid cells, interfering with synthesis of 
DNA. Alternatively, immunosuppression may be brought about by blocking 
   
the synthesis of RNA (possibly messenger RNA), inhibiting processing of 
antigens prior to lymphocyte stimulation. Therapy with azathioprine in doses 
of 1.5 to 2.0 mg/kg per day is generally added to cyclosporine as a means of 
decreasing the requirements for the latter. Because azathioprine is rapidly 
metabolized by the liver, its dosage need not be varied directly in relation to 
kidney function, even though kidney failure results in retention of the 
metabolites of azathioprine. Reduction in dosage is required because of 
leukopenia and occasionally thrombocytopenia. Excessive amounts of 
azathioprine may also cause jaundice, anaemia, and alopecia.  
 
Mycophenolate mofetil is now used in place of azathioprine in many 
centers. It has a similar mode of action and a mild degree of gastrointestinal 
toxicity but produces minimal bone marrow suppression. Its advantage is its 
increased potency in preventing or reversing rejection.  
 
Glucocorticoids are important adjuncts to immunosuppressive 
therapy. Prednisone has effects that are easiest to assess, and in large doses it 
is usually effective for the reversal of rejection. In general, 200 to 300 mg 
prednisone is given immediately prior to or at the time of transplantation, and 
the dosage is reduced to 30 mg within a week. The side effects particularly 
impairment of wound healing and predisposition to infection, make it 
desirable to taper the dose as rapidly as possible. 
   
 A major effect of steroids is on the monocyte-macrophage system, 
preventing the release of interleukin (IL) 6 and IL-1. Lymphopenia after large 
doses of glucocorticoids is primarily due to sequestration of recirculating 
blood lymphocytes to lymphoid tissue.  
 
Cyclosporine is a fungal peptide with potent immunosuppressive 
activity. It is a cyclic 11- amino peptide derived from the fungus. It has a 
narrow therapeutic window. It acts on the calcineurin pathway to block 
transcription of mRNA for IL3-2 and other proinflammatory cytokines, 
thereby inhibiting T cell proliferation. Since it blocks production of IL-2 by T 
cells, its combination with steroids is expected to produce a double block in 
the macrophage-IL-6/IL-1- T cell- IL-2 sequence. Of its toxic effects 
(nephrotoxicity, hepatotoxicity, hirsutism, tremor, gingival hyperplasia, 
diabetes), only nephrotoxicity presents a serious management problem.  
 
The increased cardiovascular risk profile as a result of cyclosporine is 
ascribed to both a quantitative increase in LDL particles and an increased 
oxidizability of the LDL particles. Use of it is also associated with increased 
plasma lipoprotein(a) (Lp[a]) and homocysteine levels, In addition, It has 
unfavorable effects on the fibrinolytic system also. Cyclosporine leads to an 
elevation of BP. These side effects contributes to the high cardiovascular 
morbidity & to an accelerated loss of graft function. 
   
Tacrolimus (FK-506) is a fungal macrolide that has the same mode of 
action, and a similar side effect profile, as cyclosporine. It does not produce 
hirsutism or gingival hyperplasia, however. De novo induction of diabetes 
mellitus is more common with tacrolimus.  
 
Conversion from cyclosporine to tacrolimus reduced not only the 
serum concentration of LDL cholesterol but also the oxidizability of the LDL 
particle. The reduced oxidizability of the LDL particles is likely to be 
associated with the concurrent decrease in serum triglycerides.  Reduced 
levels of serum triglycerides and apolipoprotein B are associated with an 
altered, less dense composition of the LDL particles. These lighter LDL 
particles contain more lipids compared with the protein component, resulting 
in conformational changes with a diminished access for free radicals and pro-
oxidants such as copper to cause oxidation of the fatty acids. Furthermore, 
lighter LDL particles are more easily cleared from the circulation by the high-
affinity LDL receptor, leading to a shorter plasma residence time, during 
which the particle is susceptible to in vivo oxidation.  
 
Sirolimus (previously called rapamycin) is another fungal macrolide 
but has a different mode of action, i.e., it inhibits T cell growth factor 
pathways, preventing the response to IL3-2 and other cytokines. It can be 
used in conjunction with cyclosporine or tacrolimus as an alternative 
immunosuppressive regimen.  
   
Antibodies to Lymphocytes When serum from animals made immune 
to host lymphocytes is injected into the recipient, a marked suppression of 
cellular immunity to the tissue graft results. A globulin fraction of serum 
[antilymphocyte globulin (ALG)] is the agent generally employed. For use 
in humans, peripheral human lymphocytes, thymocytes, or lymphocytes from 
spleens or thoracic duct fistulas have been injected into horses, rabbits, or 
goats to produce antilymphocyte serum, from which the globulin fraction is 
then separated.  
 
Monoclonal antibodies against defined lymphocyte subsets offer a 
more precise and standardized form of therapy. OKT3 is directed to the CD3 
molecules that form a portion of the T cell antigen-receptor complex; hence 
CD3 is expressed on all mature T cells. CD4 or CD8 molecules also form part 
of the fully activated cluster of molecules, and monoclonal antibodies to these 
offer the potential for more selective targeting of T cell subsets.  
 
Another approach to more selective therapy is to target the 55-kDa 
alpha chain of the IL3-2 receptor, expressed only on T cells that have been 
recently activated. The problem with such mouse antibodies is the potential 
for developing human antimouse antibodies (HAMA). 
 
Genetically engineered monoclonal antibodies can solve this problem. 
Two such antibodies to the IL-2 receptor, in which either a chimeric protein 
has been made between mouse Fab with human Fc (basiliximab) or 
   
"humanized" by splicing the combining sites of the mouse into a molecule 
that is 90% human IgG (daclizumab), have been approved for prophylaxis of 
acute rejection in the immediate posttransplant period. They are effective at 
decreasing the acute rejection rate and have few adverse side effects.  
 
LIPOPROTEIN METABOLISM 
 Lipoproteins are large, mostly spherical complexes that transport lipids 
(primarily triglycerides, cholesteryl esters), and fat-soluble vitamins through 
body fluids (plasma, interstitial fluid, and lymph) to and from tissues. They 
play an essential role in the absorption of dietary cholesterol, long-chain fatty 
acids, and fat-soluble vitamins; the transport of triglycerides, cholesterol, and 
fat-soluble vitamins from the liver to peripheral tissues; and the transport of 
cholesterol from peripheral tissues to the liver.  
 
Lipoproteins contain a core of hydrophobic lipids (triglycerides and 
cholesteryl esters) surrounded by hydrophilic lipids (phospholipids, 
unesterified cholesterol) and proteins that interact with body fluids. The 
plasma lipoproteins are divided into five major classes based on their relative 
densities): chylomicrons, very low density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and 
high-density lipoproteins (HDL).  
 
Each lipoprotein class comprises a family of particles that vary slightly 
in density, size, migration during electrophoresis, and protein composition. 
   
The density of a lipoprotein is determined by the amount of lipid and protein 
per particle. HDL is the smallest and most dense lipoprotein, whereas 
chylomicrons and VLDL are the largest and least dense lipoprotein particles. 
Most triglyceride is transported in chylomicrons or VLDL, and most 
cholesterol is carried as cholesteryl esters in LDL and HDL.  
 
The apolipoproteins are required for the assembly and structure of 
lipoproteins. Apolipoproteins also serve to activate enzymes important in 
lipoprotein metabolism and to mediate the binding of lipoproteins to cell-
surface receptors. ApoA-I, which is synthesized in the liver and intestine, is 
found on virtually all HDL1 particles. ApoA-II is the second most abundant 
HDL apolipoprotein and is found on approximately two-thirds of all HDL 
particles.  
 
ApoB is the major structural protein of chylomicrons, VLDL, IDL, and 
LDL. One molecule of apoB, either apoB-48 (chylomicrons) or apoB-100 
(VLDL, IDL, or LDL), is present on each lipoprotein particle. The human 
liver makes only apoB-100, and the intestine makes apoB-48. ApoE is present 
in multiple copies on chylomicrons, VLDL, and IDL and plays a critical role 
in the metabolism and clearance of triglyceride-rich particles. Three 
apolipoproteins of the C-series (apoC-I, -II, and -III) also participate in the 
metabolism of triglyceride-rich lipoproteins.  
 
   
TRANSPORT OF DIETARY LIPIDS (EXOGENOUS PATHWAY)  
Dietary triglycerides are hydrolyzed by pancreatic lipases within the 
intestinal lumen and are emulsified with bile acids to form micelles. Dietary 
cholesterol and retinol are esterified (by the addition of a fatty acid) in the 
enterocyte to form cholesteryl esters and retinyl esters, respectively.  
 
Longer-chain fatty acids (>12 carbons) are incorporated into 
triglycerides and packaged with apoB-48, cholesteryl esters, retinyl esters, 
phospholipids, and cholesterol to form chylomicrons. Nascent chylomicrons 
are secreted into the intestinal lymph and delivered directly to the systemic 
circulation, where they are extensively processed by peripheral tissues before 
reaching the liver. The particles encounter lipoprotein lipase (LPL), which is 
anchored to proteoglycans that decorate the capillary endothelial surfaces of 
adipose tissue, heart, and skeletal muscle. The triglycerides of chylomicrons 
are hydrolyzed by LPL, and free fatty acids are released; apoC-II, which is 
transferred to circulating chylomicrons, acts as a cofactor for LPL in this 
reaction. The released free fatty acids are taken up by adjacent myocytes or 
adipocytes and either oxidized or reesterified and stored as triglyceride. Some 
free fatty acids bind albumin and are transported to other tissues, especially 
the liver.  
 
The chylomicron particle progressively shrinks in size as the 
hydrophobic core is hydrolyzed and the hydrophilic lipids (cholesterol and 
   
phospholipids) on the particle surface are transferred to HDL. The resultant 
smaller, more cholesterol ester-rich particles are referred to as chylomicron 
remnants. The remnant particles are rapidly removed from the circulation by 
the liver in a process that requires apoE.  
 
TRANSPORT OF HEPATIC LIPIDS (ENDOGENOUS PATHWAY)  
This one refers to the hepatic secretion and metabolism of VLDL to 
IDL and LDL. VLDL particles resemble chylomicrons in protein composition 
but contain apoB-100 rather than apoB-48 and have a higher ratio of 
cholesterol to triglyceride (~1 mg of cholesterol for every 5 mg of 
triglyceride). The triglycerides of VLDL are derived predominantly from the 
esterification of long-chain fatty acids.  
 
The packaging of hepatic triglycerides with the other major 
components of the nascent VLDL particle (apoB-100, cholesteryl esters, 
phospholipids, and vitamin E) requires the action of the enzyme microsomal 
transfer protein (MTP). After secretion into the plasma, VLDL acquires 
multiple copies of apoE and apolipoproteins of the C series. The triglycerides 
of VLDL are hydrolyzed by LPL, especially in muscle and adipose tissue. 
 
As VLDL remnants undergo further hydrolysis, they continue to shrink 
in size and become IDL, which contain similar amounts of cholesterol and 
triglyceride. The liver removes approximately 40 to 60% of VLDL remnants 
and IDL by LDL receptor-mediated endocytosis via binding to apoE. The 
   
remainder of IDL is remodeled by hepatic lipase (HL) to form LDL; during 
this process, most of the triglyceride in the particle is hydrolyzed and all 
apolipoproteins except apoB-100 are transferred to other lipoproteins.  
 
The cholesterol in LDL accounts for ~70% of the plasma cholesterol in 
most individuals. Approximately 70% of circulating LDLs are cleared by 
LDL receptor-mediated endocytosis in the liver. Lipoprotein(a) [Lp(a)] is a 
lipoprotein similar to LDL in lipid and protein composition, but it contains an 
additional protein called apolipoprotein(a) [apo(a)]. Apo(a) is synthesized in 
the liver and is attached to apoB-100 by a disulfide linkage. The mechanism 
by which Lp(a) is removed from the circulation is not known.  
 
HDL METABOLISM AND REVERSE CHOLESTEROL TRANSPORT  
All nucleated cells synthesize cholesterol but only hepatocytes can 
efficiently metabolize and excrete cholesterol from the body. The 
predominant route of cholesterol elimination is by excretion into the bile, 
either directly or after conversion to bile acids. Cholesterol in peripheral cells 
is transported from the plasma membranes of peripheral cells to the liver by 
an HDL-mediated process termed reverse cholesterol transport. 
 
Nascent HDL particles are synthesized by the intestine and the liver. 
The newly formed discoidal HDL particles contain apoA-I and phospholipids 
(mainly lecithin) but rapidly acquire unesterified cholesterol and additional 
phospholipids from peripheral tissues via transport by the membrane protein 
   
ATP-binding cassette protein A (ABCA). Once incorporated in the HDL 
particle, cholesterol is esterified by lecithin-cholesterol acyltransferase 
(LCAT), a plasma enzyme associated with HDL. As HDL acquires more 
cholesteryl ester it becomes spherical, and additional apolipoproteins and 
lipids are transferred to the particles from the surfaces of chylomicrons and 
VLDL during lipolysis.  
 
HDL cholesterol is transported to hepatoctyes by both an indirect and a 
direct pathway. HDL cholesteryl esters are transferred to apoB-containing 
lipoproteins in exchange for triglyceride by the cholesteryl ester transfer 
protein (CETP). The cholesteryl esters are then removed from the circulation 
by LDL receptor-mediated endocytosis. HDL cholesterol can also be taken up 
directly by hepatocytes via the scavenger receptor class BI (SR-BI), a cell-
surface receptor that mediates the selective transfer of lipids to cells.  
 
HDL particles undergo extensive remodeling within the plasma 
compartment as they transfer lipids and proteins to lipoproteins and cells. For 
example, after CETP-mediated lipid exchange, the triglyceride-enriched HDL 
becomes a subbstrate for HL, which hydrolyzed the triglycerides and 
phospholipids to generate smaller HDL particles. 
   
 
Transport of endogenous hepatic lipids via VLDL, IDL, and LDL. Note the 
relative and absolute changes in apoproteins, other than apo B100, as VLDL 
is converted to IDL and LDL. The sites of action of the two lipases, LPL and 
HTGL, are denoted.  
Transport of exogenously derived lipids from the intestine to peripheral 
tissues and liver via the chylomicron system.  
HDL metabolism and the role of HDL in reverse cholesterol transport. Free 
cholesterol is accepted from peripheral tissues by HDL3 and, after 
esterification, may be transferred to apo B100 lipoproteins.  
   
 
Dyslipidemia in kidney Transplants:- 
            Dyslipidemia, alone or as part of the metabolic syndrome, is an 
established risk factor for CVD mortality in kidney transplant  recipients , The 
main causes are thought to be steroids, calcineurin inhibitors, sirolimus, 
Diuretics and Betablockers.  
 
About 60% of kidney transplant recipients have a total cholesterol 
level greater than 240 mg/dL (6.21 mmol/L); and low-density lipoprotein 
cholesterol (LDL-C) greater than 130 mg/dL (3.36 mmol/L); about 35% have 
hypertriglyceridemia. Low levels of high-density lipoprotein cholesterol (<35 
mg/dL [0.91 mmol/L]) occur in about 15% of kidney transplant recipients-a 
percentage similar to that in the general population. The concentrations of 
lipoprotein(a) and small, dense LDL-C, which are atherogenic, is increased.  
 
   
Oxidatively modified LDL cholesterol is a chemotactic factor for 
monocytes and macrophages, both in vascular endothelium and in kidney 
glomeruli, and it may cause activation of endothelial cells, smooth muscle 
cells, mesangial cells, and macrophages. Studies showed deposition of LDL 
and oxidized LDL in a mesangiocapillary way in the glomeruli, in endothelial 
cells, and in the interstitial space. The amount of oxidized LDL 
immunostaining was related to the increase in the density of macrophages in 
the tubulointerstitial compartment and to the extent of interstitial fibrosis.  
 
Cyclosporine increases serum LDL cholesterol level by inhibiting the 
synthesis of LDL receptors in the liver, thereby interfering with the LDL 
receptor–mediated catabolism in the liver. The improvement in serum LDL 
cholesterol level after conversion to tacrolimus might be due to the 
withdrawal of this inhibition of the LDL receptor production. The 
atherogenicity of LDL cholesterol depends not only on its serum 
concentration but also on the oxidizability of the particles.  
 
Interestingly, the vascular lesions of chronic allograft nephropathy seen 
on allograft biopsy resemble those of atherosclerosis. Because of the high 
prevalence of CVD in transplant recipients, it is reasonable to consider the 
kidney transplant state to be “coronary heart disease risk equivalent” when 
applying the guidelines.  
   
Immunosuppressants in Kidney transplants: 
CYCLOSPORINE  
Lipid profile abnormalities starts within one month of initiation of 
therapy. Typically it includes increases upto 30% in total cholesterol, 21 to 
69%in triglyceride, 5 to 57%in LDL, 0 to 61%  HDL, It also produces an 
increased oxidizadility of LDL particles & increased plasma lipoprotein  LP 
and homocysteine level. It produces unfavourable effect on fibrinolytic 
system also.  
 
Tacrolimus usage is associated with less unfavourable effects on 
hypertension  and lipid profile. With conversion to tacrolimus reduction in  
LDL level and the LDL particles are less susceptible to oxidation.  
 
Antiproliferative agents. Sirolimus has been shown to increase apo B -100, 
apo C –II,  apo C – III,and hepatic VLDL cholesterol  production and to 
decrease heparin induced LPL activity. Often results in increased total 
cholesterol and triglyceride. This effect appears to be greater than with 
cyclosporine or tacrolimus.   
 
Corticosteroids  It enhance activity of acetyl–coenzyme A carboxylase, 3–
hydroxy 3- methyl glutaryl-coenzyme A and free fatty acid synthase and 
inhibit  LPL activity. So steroids enhance cholesterol production and prevent 
the breakdown of TG rich particles. Combination of steroids with 
immunosuppressive agents have additive effects due to different mechanisms 
of lipid profile alteration. 
 
   
Anti Hypertensive drugs in Kidney Transplants: 
1) Beta blockers 
 They increase TG & reduce HDL. Those with Beta 1 selectivity & 
partial agonistic activity have less effect on lipid profile. Non selective Beta 
blockers reduce HDL up to 20% and raise TG up to 50%. VLDL/TG 
metabolism retarded in the setting of unopposed alpha adrenergic stimulation 
of lipoprotein lipase activity. So low VLDL metabolism results in reduction 
of HDL. 
 
ii) Loop Diuretic & Thiazides 
 They increase the plasma concentration of TC,TG, LDL & Decrease 
HDL average 5 to 20% during initiation of treatment. It may be related to 
ECV depletion and Nacl restriction. Also hypokalemia mediated reduced 
insulin secretion may be contributory factor. Serum cholesterol returns to 
baseline over 3 to 12 months of therapy. 
 
iii) Calcium Channel Blockers 
 In the usual therapeutic doses they have no effect on serum glucose, 
insulin secretion and insulin sensitivity. They do not increase TG and 
Cholesterol. No reduction of HDL seen. Ideal for diabetic and patients of 
dysmetabolic syndrome. 
 
iv) Central Alpha2 Adrenergic Agonists 
 They are neutral with respect to Lipid metabolism. 
   
Dyslipidemias as defined in the Adult Treatment Panel III Guidelines 
 
Dyslipidemia Level (mg/dL) 
Total cholesterol 
Desirable 
Borderline high 
High 
 
<200 
200–239 
>240 
LDL cholesterol 
Optimal 
Near optimal 
Borderline 
High 
Very high 
 
<100 
100–129 
130–159 
160–189 
>190 
Triglycerides 
Normal 
Borderline high 
High 
Very high 
 
<150 
150–199 
200–499 
>500 
HDL cholesterol 
Low 
 
<40 
 
Factors associated with post-transplant dyslipidemia 
TRADITIONAL RISK FACTORS 
1. Male gender 
2. Genetic predisposition 
3. Increased age 
4. Proteinuria 
   
5. Kidney dysfunction 
6. Medications 
 Immunosuppressive agents 
 Calcineurin inhibitors (cyclosporine, tacrolimus) 
 Antiproliferative agents (sirolimus) 
 Corticosteroids 
 Antihypertensive agents 
 Diuretics 
 Beta-blockers 
 
NONTRADITIONAL RISK FACTORS 
1. Homocysteine 
2. Oxidative stress 
3. Proteinuria 
4. Inflammation 
5. C-reactive protein 
6. Left ventricular hypertrophy 
7. Hyperparathyroidism 
8. Thrombogenic factors. 
 
Mechanisms of Iatrogenic dyslipidemia in kidney transplant recipients 
1. Reduction of bile acid synthesis 
2. Altered hepatic LDL receptor activity 
   
3. Increased hepatic triglyceride lipase activity 
4. Inhibition of lipoprotein lipase.  
5. Increased lecithin-cholesterol acyltransferases.  
6. Increased LDL oxidation 
7. Enhanced HMG-CoA activity 
8. Enhanced acety1-coenzyme A carboxylase. 
9. Increased free fatty acid synthetase 
 
Key features of the NKF-K/DOQI Guidelines that differ from those of 
the National Cholesterol Education Program Adult Treatment Panel II 
NKF-K/DOQI Guidelines 
1. CKD and kidney transplant patients should be considered to be in the 
highest risk category and evaluation of dyslipidemias should occur at 
presentation after a change in status, and annually as well. 
2. Drug therapy should be used for LDL 100–129 mg/dL after 3 months 
of TLC. 
3. Initial drug therapy for high LDL should be with a statin. 
4. Fibrates may be used in Stage 5 CKD 
a) For patients with triglycerides >500 mg/dL; and  
b)  For patients with triglycerides >200 mg/dL with non-HDL 
Cholesterol >130 mg/dL, who do not tolerate statins. 
5. Gemfibrozil may be the fibrate of choice for treatment of high 
triglycerides in patients with CKD and kidney transplant patients 
   
Causes of death among patients, treated with hemodialysis, peritoneal 
dialysis, or kidney transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
THE MANAGEMENT OF DYSLIPIDEMIAS IN ADULT KIDNEY 
TRANSPLANT RECIPIENTS 
 
Dyslipidemia 
(mg/dL) 
 
Goal 
(mg/dL) 
Initiate Increase 
TG >500  
 
LDL 100–129  
 
LDL >130  
 
TG >200 and 
Non-HDL >130 
<500  
 
<100  
 
<100  
 
Non-HDL 
<130 
TLC 
 
TLC 
 
Low dose statin 
 
TLC+  
Low dose statin 
Fibrate or Niacin 
 
Low dose statin  
 
Max. dose statin 
 
 
Max. dose statin 
 
 
 
THERAPEUTIC LIFESTYLE CHANGES (TLC) FOR ADULT 
KIDNEY TRANSPLANT RECIPIENTS 
 
Diet (consult a dietitian with expertise in chronic kidney disease) 
 
1. Emphasize reduced saturated fat 
2. Saturated fat: <7% of total calories 
3. Polyunsaturated fat: up to 10% of total calories 
4. Monounsaturated fat: up to 20% of total calories 
5. Total fat: 25–35% of total calories 
6. Cholesterol: <200 mg per day 
7. Carbohydrate: 50–60% of total calories 
8. Emphasize components that reduce dyslipidemia 
9. Fiber: 20–30 g per day, emphasize 5–10 g per day viscous  
(soluble) fiber. 
   
10. Consider plant stanols/sterols 2 g per day 
11. Improve glycemic control 
12. Emphasize total calories to attain/maintain standard  
NHANES body weight  
13. Match intake of overall energy  (calories) to overall energy needs. 
14. Body mass index 25–28 kg/m2 
15. Waist circumference 
Men <40 inches (102 cm) 
Women <35 inches (88 cm) 
16. Waist–hip ratio (men <1.0; women <0.8) 
Physical activity 
1. Moderate daily lifestyle activities 
2. Use pedometer to attain/maintain 10,000 steps per day 
3. Emphasize regular daily motion and distance (within ability) 
4. Moderate planned physical activity 
 3–4 times per week 20–30 minute periods of activity 
 Include 5-minute warm-up and cool-down 
 Choose walking, swimming, supervised exercise (within ability) 
 Include resistance exercise training 
5. Emphasize lean muscle mass and reducing excess body fat 
Habits 
 Alcohol in moderation: limit one drink per day with approval of 
physician. 
 Smoking cessation. 
   
 
Exercise training produces small, but significant improvements in 
dyslipidemias. It has a number of beneficial effects, independent of those on 
dyslipidemias, and the lack of adverse effects makes a compelling case for 
recommending exercise in patients at risk for ACVD. The reduction in LDL 
that can be achieved with TLC is generally modest. Therefore, TLC alone is 
usually insufficient to reduce the LDL to the goal of <100mg/dL 
(<2.59mmol/L). In patients who cannot reduce LDL to <100mg/dL 
(<2.59mmol/L) by diet, a statin should be prescribed, Diet should be 
continued as an adjunct to the statin. Strategy to find out the lowest effective 
dose that achieves the goal, will minimize the frequency and severity of 
adverse effects. 
 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
("statins") are currently the most effective agents for lowering LDL-C levels. 
Statins are coadministered with other substrates of CYP3A4 enzymes. 
Generally, in patients who are also taking a calcineurin inhibitor, the statin 
dose should be reduced to about half the standard dose.  
 
To minimise statin toxicity, start with low dose statin. Use of 
pravastatin or Fluvastatin had associated with least interaction with 
Cycloporine. Periodic checking of plasma CK and Liver function tests 
recommended. 
 
   
 The reduction in mortality and in CHD events is proportional to the 
reduction in LDL. Statins are safe and effective in reducing LDL in kidney 
transplant recipients. Furthermore, statins reduce the incidence of cardiac 
death and acute myocardial infarction in these patients, Elevated hepatic 
transaminases occur in 0.5–2.0% of patients treated with statins in the general 
population. Therefore, baseline alanine and aspartate transferase levels 
should be obtained. Statins have not been shown to worsen outcomes in 
patients with chronic transaminase elevations due to hepatitis B or C.  
 
Patients should also be monitored for signs and symptoms of 
myopathy. The risk of myopathy from statins is increased by CKD, advanced 
age, small body frame, and concomitant medications (e.g. fibrates, nicotinic 
acid, cyclosporine, azole antifungals, macrolide antibiotics, protease 
inhibitors, nondihydropyridine calcium antagonists, and amiodarone). 
Obtaining a baseline creatinine phosphokinase (CK) level will help in the 
interpretation of subsequent CK levels.  
 
Patients who develop muscle pain or tenderness should discontinue 
statin therapy immediately and have CK levels measured. Elevations greater 
than 10 times the upper limit of normal are indicative of myositis and require 
atleast temporary cessation of statin therapy. For patients with muscle 
soreness and either normal or mildly elevated CK, levels should be measured 
weekly, and the patient’s symptoms monitored closely. Frequently, symptoms 
may improve with a reduction in the dose of the statin. However, if symptoms 
worsen, the statin should be discontinued.  
   
 
Recommended daily statin dose ranges 
 
Level of GFR (mL/min/1.73 m2) Statin 
 
>30 
 
<30 or dialysis 
 
With cyclosporine 
 
Atorvastatin 
 
Fluvastatin 
 
Lovastatin 
 
Pravastatin 
 
Simvastatin 
 
 
10–80 mg 
 
20–80 mg 
 
20–80 mg 
 
20–40 mg 
 
20–80 mg 
 
 
10–80 mg 
 
10–40 mg 
 
10–40 mg 
 
20–40 mg 
 
10–40 mg 
 
 
10–40 mg 
 
10–40 mg 
 
10–40 mg 
 
20–40 mg 
 
10–40 mg 
 
 
 
Maximum doses of fibrates in patients with reduced kidney function 
 
Dose (mg) by level of GFR (mL/min/1.73 m2) 
 
 
Fibrate 
 >90 
 
60–90 
 
15–59 
 
<15 
 
Bezafibrate 
 
Clofibrate 
 
Fenofibrate 
 
Gemfibrozil  
200 tid 
 
1,000 bid 
 
201 qd 
 
600 bid 
 
200 bid 
 
1,000 qd 
 
134 qd 
 
600 bid 
 
200 qd 
 
500 qd 
 
67 qd 
 
600 bid
 
 
Avoid 
 
Avoid 
 
Avoid 
 
600 bid 
 
Chronic allograft nephropathy (CAN) is the main cause of late graft 
loss in kidney transplantation. The pathogenesis of CAN is multifactorial. The 
initiating factors are probably mainly immunologic, whereas the perpetuating 
   
factors are considered to be largely nonimmunologic, including 
hyperlipidemia and hypertension.  
 
               The most significant factors associated with CV events were as 
follows: gender, length of smoking, diabetes mellitus.  Of note, even a 
nonfatal posttransplantation myocardial infarction may predict future graft 
failure and death. Peripheral vascular disease (cerebral vascular disease and 
lower extremity vascular disease) afflicts at least 15% of all kidney transplant 
recipients in a 10- to 15-yr period posttransplantation.  
 
 In recognition that lipid alterations in these patients are linked with 
development of ischemic heart disease, vascular mortality, and graft 
deterioration, the National Kidney Foundation has recently released 
guidelines suggesting a low-density-lipoprotein (LDL) cholesterol goal of < 
100 mg/dL for these patients. Statins and diet therapy are recommended as 
first-line agents for achieving goal LDL cholesterol levels in this population. 
 
All statins can provide a 30 to 40% reduction in LDL cholesterol 
levels. Patients who require maximal LDL cholesterol lowering may be 
treated with atorvastatin or simvastatin, whereas patients with low HDL 
cholesterol may have a greater advantage from simvastatin use and those with 
elevated triglycerides may benefit from high-dose atorvastatin. The final 
choice of statins should be left to the judgment of the treating physician. For 
the treatment of hypertriglyceridemia, particularly in patients who are treated 
   
with sirolimus, gemfibrozil may be the fibric derivative of choice. Although 
nicotinic acid derivatives also could be used, fibric acid derivatives are better 
tolerated. Bile acid sequestrants such as cholestyramine, colestipol, and 
colesevelam hydrochloride alter the bioavailability of immunosuppressants 
and also may increase triglyceride levels. Ezetimibe was used recently alone 
and in combination with statins to reduce LDL cholesterol in a small-size 
study with kidney transplant patients. Antilipemic drugs may have significant 
interactions between the classes and with immunosuppressant agents. Statins 
and fibrates interact with CNI and may result in hepatitis, myositis, and 
rhabdomyolysis. The prevalence of these untoward effects is minimal in our 
contemporary era of immunosuppression in the absence of high-dose fibrate 
or statin therapy and with close monitoring.  
 
In summary, adult kidney transplant recipients with 
hypertriglyceridemia (triglycerides 300 mg/dl, or 5.65 mmol/L) may be 
treated with fibrates, and statins can be used for LDL cholesterol levels of 100 
mg/dl (2.59 mmol/L;). Treatment of proteinuria and other causes of secondary 
dyslipidemia, along with therapeutic lifestyle changes including diet and 
physical activity, always should be combined.  
 
The National Kidney Foundation Task Force on Cardiovascular 
Disease recommends that kidney transplant recipients are considered as being 
in the highest risk category when these guidelines are applied. Therefore, the 
goal for the LDL-C value for kidney transplant recipients should generally be 
100 mg/dL (2.59 mmol/L).  
   
 
 
 
 
 
MATERIALS AND 
METHODS 
   
MATERIALS AND METHODS 
 
Setting  :  kidney  transplant patients attending transplant op,  of 
Nephrology Department and healthy volunteers attending Medicine OPD. 
Collaborating Departments    : Department of Nephrology 
       Madurai Medical College 
       Madurai.  
       Department of Biochemistry 
       Madurai Medical College  
       Madurai 
Design of the study     : Descriptive study 
Period of study      : 1.8.2005 to 31.5.2006 
Sample size         : 40 
Selection of the study subjects  
40 kidney transplant patients attending Transplant OPD, Department of 
Nephrology,Govt. Rajaji Hospital between 1.8.2005 to 31.5.2006 formed the 
study group.  
 
DEFINITIONS  
Chronic kidney disease (CKD) At least 3 months of either: 1) structural or 
functional abnormalities of the kidney that can lead to kidney failure; or 2) 
GFR <60 mL/min/1.73m2 
   
 
Cardiovascular Disease (CVD) Coronary heart disease, cerebrovascular 
disease, renal artery stenosis, peripheral vascular disease, congestive heart 
failure, or left ventricular hypertrophy 
 
Atherosclerotic cardiovascular disease (ACVD)Coronary heart disease, 
cerebrovascular disease, renal artery stenosis, or peripheral vascular disease 
 
Coronary heart disease (CHD) Atherosclerotic disease of the coronary 
arteries that causes myocardial ischemia 
 
Cerebrovascular disease Atherosclerotic disease of the cerebral arteries that 
causes strokes and transient ischemic attacks 
 
Peripheral vascular disease Atherosclerotic disease of arteries that causes 
ischemia of the extremities 
 
Dyslipidemia Any abnormality in plasma lipoprotein concentration or 
composition that is associated with an increased risk for atherosclerotic 
cardiovascular disease 
 
Lipid profile Plasma levels of total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol and triglycerides 
 
GFR glomerular filtration rate. 
 
   
Inclusion criteria  
 40 kidney transplant patients attending Transplant OPD, Nephrology 
department. 
Exclusion criteria  
1. Kidney failure 
2. Clinical and or laboratory evidence of graft rejection 
3. Acute or chronic infections 
4. Diabetes,  
5. Hypothyroidism,  
6. Liver disease,  
7. Excessive alcohol consumption and smoking. 
8. Nephrotic syndrome  
 
Methods  
History  1. Diabetes mellitus  
2. Family history of premature CAD           
3. Dietary habits,   
4. Probable cause of kidney failure  
5. Time lag prior to transplant  
6. Mode of renal replacement therapy offered prior to  
    transplant  
7. Nature of donor &  compatibility  
8. Drug regimen  
   
9. Amount of weight gain  
10. Intercurrent infections  
11. Any rejection episodes & hospitalization in the   
      recent past   
12. Other comorbid medical illness           
 
Clinical Examination    
1. Height, weight, Body mass index  
2. Vital parameters  
3. Major systems examination  
4. Evidence of active infections / graft rejection.  
Laboratory Procedure 
Blood was drawn after an overnight fast, during morning hours in 
sitting position. 
 
Investigations   
1. Serum Lipid Profile (12hours fasting sample)  
2. Renal parameters (Blood urea, Serum creatinine)  
3. Urine spot protein creatinine ratio  
4. Fasting plasma Glucose.  
 
All specimens were analysed within  4 to 6 hours of collection. Total 
cholesterol and triglycerides in the plasma were measured enzymaically and 
then the  cholesterol in the supernant is measured after precipitation of APO- 
   
B containing lipoproteins to determine the  HDL cholesterol . LDL 
cholesterol is estimated by using the friedewald formula. 
  
FRIEDEWALD FORMULA appears to be the most practical reliable 
method for determining LDL cholesterol in clinical practice. 
 
LDL  CHOLESTEROL= CHOLESTEROL – HDL-( TRIGLYCERIDE /5)  
VLDL is estimated by dividing the plasma triglycerides by 5 reflecting 
the ratio of cholesterol to triglyceride in VLDL particles. This formula is 
reasonably accurate if test results are obtained on fasting plasma and if the 
triglyceride level is less than 350 mg / dl. The accurate determination of LDL-
C levels in patients with triglyceride levels greater than this requires 
application of Ultra centrifugation techniques (Beta Quantification). 
 
Ethical committee approval  : Obtained  
Consent     : Informed consent was obtained  
Financial support     : Nil  
Conflict of interest    : Nil  
   
 
 
 
 
 
 
RESULTS AND ANALYSIS 
   
RESULTS AND ANALYSIS 
 
A:CHARACTERISTICS OF RENAL TRANSPLANT (STUDY) CASES 
AND NORMAL HEALTHY CASES 
 
Table 1 Age  
 
Study Cases Controls Age 
No % No % 
< 40 
> 40 
29 
11 
72.5 
27.5 
30 
10 
75 
25 
Total 40 100 40 100 
Range 
Median 
Mean 
S.D 
26 – 46 
36 
36.4 
5.9 
25 – 46 
34 
34.7 
6.5 
P 0.1898 (Not Significant) 
 
 There is no statistically significant difference in the age composition of 
the study and control cases. 
 
   
Table 2 Sex 
 
Study Cases Controls Sex 
No % No % 
Male 
Female 
33 
7 
82.5 
17.5 
30 
10 
75 
25 
 
p = 0.5846 (Not Significant) 
 
 The sex composition of the two groups does not have significant 
difference. 
  
   
Table 3 BMI 
 
Study Cases Controls BMI 
No % No % 
Normal (< 25) 
Cases (> 25) 
29 
11 
72.5 
27.5 
30 
10 
75 
25 
Range 
Median 
Mean 
S.D 
18.4 – 28.6 
23.2 
23.1 
2.5 
19.4 – 27.0 
23.1 
23.4 
2.0 
P 0.5799 (Not Significant) 
  
The BMI of the two groups does not difference significantly. 
 
Table 4 Free Cholesterol 
 
Study Cases Controls Free Cholesterol 
No % No % 
Normal (150-200 mg) 
Above normal (>200 mg) 
27 
13 
67.5 
32.5 
35 
5 
87.5 
12.5 
Range 
Median 
Mean 
S.D 
150 – 250 
180 
194.5 
36.1 
140 – 260 
170 
179.1 
27.6 
p 0.0663 
  
The mean values of free cholesterol in the study group is higher than 
that of the control group. But the difference is statistically not significant. 
   
Table 5 TGL 
 
Study Cases Controls TGL 
No % No % 
Normal (75-150 mg) 
Above Normal (> 150) 
35 
5 
87.5 
12.5 
37 
3 
92.5 
7.5 
Range 
Median 
Mean 
S.D 
100 – 180 
135 
135.5 
23.7 
90 – 120 
120 
124.5 
28.9 
P 0.0142 
  
There exists statistically significant difference in the TGL values in the 
two groups. 
Table 6 VLDL 
 
Study Cases Controls VLDL 
No % No % 
Normal (20-40 mg) 
Above Normal (> 40) 
40 
- 
100 
- 
39 
1 
97.5 
2.5 
Range 
Median 
Mean 
S.D 
20 – 36 
27 
27.1 
4.8 
18 – 42 
24 
25.0 
5.8 
p 0.0236 
  
The difference in the VLDL values of the two groups is statistically 
significant. 
   
Table 7 HDL 
 
Study Cases Controls HDL 
No % No % 
Normal (30-60 mg) 
Below normal (30) 
40 
- 
100 
- 
40 
- 
100 
- 
Range 
Median 
Mean 
S.D 
30 – 60 
50 
48 
8.0 
40 – 60 
50 
52 
7.4 
p 0.012 
  
The difference in the HDL values of the two groups is statistically 
significant. 
Table 8 LDL 
 
Study Cases Controls LDL 
No % No % 
Normal (80-150 mg) 
Above normal (> 150 mg) 
32 
8 
80 
20 
39 
1 
97.5 
2.5 
Range 
Median 
mean 
S.D 
80 – 200 
120 
121.7 
33.3 
70 – 168 
96 
102.2 
22.3 
p 0.0222 
 
The difference in the LDL values of the two groups is statistically 
significant. 
   
Table 9 Free Cholesterol 
 
Free Cholesterol  
Range Median Mean S.D P 
Age  
<40 (29) 
> 40 (11) 
 
150 – 270 
150 – 280 
 
180 
190 
 
192.8 
199.1 
 
34.8 
40.6 
 
0.6798 (Not 
Significant) 
Sex  
Male (33) 
Female (7) 
 
150 – 280 
150 – 230 
 
190 
160 
 
199.4 
171.4 
 
36.1 
27.9 
 
0.0271 
(Significant) 
BMI 
Normal (29) 
Obese (11) 
 
150 – 240 
150 – 280 
 
180 
240 
 
183.1 
224.5 
 
27.3 
40.3 
 
0.0027 
(Significant) 
Follow up 
< 12 months 
> 12 months  
 
150 – 280 
150 – 240 
 
230 
180 
 
216 
181.6 
 
41.9 
25.1 
 
0.0121 
(Significant) 
Regimen 
2 Drugs 
3 Drugs 
 
150 – 240 
150 – 280 
 
180 
230 
 
181.6 
216 
 
25.1 
41.9 
 
0.0121 
(Significant) 
 
 Free cholesterol values have statistically significant relationship with 
Sex, BMI, follow up period and drug regimen of the patient. Their 
relationship is not significant with age. 
   
Table 10 TGL 
 
TGL  
Range Median Mean S.D P 
Age  
<40 
> 40 
 
100 – 180 
120 – 180 
 
130 
150 
 
132.4 
143.6 
 
25.6 
16.3 
 
0.1274 (Not 
Significant) 
Sex  
Male 
Female 
 
100 – 180 
110 – 180 
 
140 
120 
 
135.2 
137.1 
 
22.8 
29.8 
 
0.8 (Not 
Significant) 
BMI 
Normal  
Obese 
 
100 – 180 
100 – 180 
 
130 
150 
 
130.7 
148.2 
 
2.7 
22.7 
 
0.0185 
(Significant)
Follow up 
< 12 months 
> 12 months  
 
120 – 180 
100 – 170 
 
150 
130 
 
150 
126.8 
 
21.7 
20.8 
 
0.0038 
(Significant)
Regimen 
2 Drugs 
3 Drugs 
 
100 – 170 
120 – 180 
 
130 
150 
 
126.8 
150 
 
20.8 
21.7 
 
0.0038 
(Significant)
 
TGL values have statistically significant relationship with BMI, follow 
up period and drug regimen of the patients, Age and Sex have no significant 
relationship will TGL value of renal transplant patients. 
   
Table 11 VLDL 
 
VLDL  
Range Median Mean S.D P 
Age  
<40 
> 40 
 
20 – 36 
24 – 36 
 
26 
30 
 
26.4 
28.7 
 
5.2 
3.3 
 
0.1239  
(Not significant)
Sex  
Male 
Female 
 
20 – 36 
22 – 36 
 
28 
24 
 
27.0 
27.1 
 
4.6 
6.2 
 
0.1448  
(Not significant)
BMI 
Normal  
Obese 
 
20 – 36 
20 – 36 
 
26 
30 
 
26.1 
29.6 
 
4.6 
4.5 
 
0.0178 
(Significant) 
Follow up 
< 12 months 
> 12 months  
 
24 – 26 
20 – 34 
 
30 
26 
 
30 
25.3 
 
4.3 
4.2 
 
0.0035 
(Significant) 
Regimen 
2 Drugs 
3 Drugs 
 
20 – 34 
24 – 36 
 
26 
30 
 
25.3 
30.0 
 
4.2 
4.3 
 
0.003 
(Significant) 
 
VLDL values have statistically significant relationship with BMI, 
follow up period and drug regimen of the patients, Age and Sex have no 
significant relationship will VLDL value of renal transplant patients. 
   
Table 12 HDL 
 
HDL  
Range Median Mean S.D P 
Age  
<40 
> 40 
 
30 – 60 
40 - 60 
 
50 
40 
 
48.8 
45.9 
 
8.0 
8.0 
 
0.2085  
(Not Significant) 
Sex  
Male 
Female 
 
35 – 60 
30 – 50 
 
50 
50 
 
48.8 
44.3 
 
7.9 
7.9 
 
0.2923  
(Not significant) 
BMI 
Normal  
Obese 
 
35 – 60 
30 – 60 
 
50 
50 
 
47.9 
48.2 
 
7.4 
9.8 
 
0.8258  
(Not significant) 
Follow up 
< 12 months 
> 12 months  
 
40 – 60 
30 – 60 
 
50 
50 
 
49.7 
47.0 
 
8.1 
7.9 
 
0.3385  
(Not significant) 
Regimen 
2 Drugs 
3 Drugs 
 
30 – 60 
40 – 60 
 
50 
50 
 
47.0 
49.7 
 
7.9 
8.1 
 
0.3385 
(Not significant) 
 
 HDL values are not significantly affected by age, sex, BMI, follow up 
period or regimen of drugs. 
   
Table 13 LDL (Taking 150 as cut off value) 
 
LDL  
Range Median Mean S.D p 
Age  
<40 (29) 
> 40 (11) 
 
80 – 200 
87 – 180 
 
96 
126 
 
117.1 
133.7 
 
32.3 
34.5 
 
0.1228  
(Not significant) 
Sex  
Male (33) 
Female (7) 
 
80 – 200 
86 – 174 
 
120 
94 
 
123.3 
114.0 
 
33.3 
34.9 
 
0.3731  
(Not significant) 
BMI 
Normal (29) 
Obese (11) 
 
80 – 170 
120 – 200 
 
94 
160 
 
108.8 
155.8 
 
26 
25.8 
 
0.0002 
(Significant) 
Follow up 
< 12 mo(15) 
> 12 mo(25)  
 
91 – 200 
80 – 150 
 
160 
95 
 
142.3 
109.3 
 
38 
23.2 
 
0.0017 
(Significant) 
Regimen 
2 Drugs(25) 
3 Drugs(15) 
 
80 – 150 
91 – 200 
 
95 
160 
 
109.3 
142.3 
 
23.2 
38 
 
0.0017 
(Significant) 
 
LDL values have statistically significant relationship with BMI, follow 
up period and drug regimen of the patients, Age and Sex have no significant 
relationship will LDL value of renal transplant patients. 
   
Table  14 : Relationship of various variables with LDL in study group 
taking 100 as cut off value for LDL 
LDL 
Normal Abnormal 
 
No % No % 
Age  
<40 (29) 
> 40 (11) 
 
15 
3 
 
51.7 
27.3 
 
14 
8 
 
48.3 
72.7 
P 0.1511 (Not significant) 
Sex  
Male (33) 
Female (7) 
 
14 
4 
 
42.4 
57.1 
 
19 
3 
 
57.6 
42.9 
P 0.3825 (Not significant) 
BMI 
Normal (29) 
Obese (11) 
 
18 
- 
 
62.1 
- 
 
11 
11 
 
37.9 
100 
P 0.0003 (Significant) 
Follow up 
< 12 months(15) 
> 12 months(25) 
 
5 
13 
 
33.3 
52 
 
10 
12 
 
66.7 
48 
P 0.4119 (Not significant) 
Regimen 
2 Drugs(25) 
3 Drugs(15) 
 
13 
5 
 
52 
33.3 
 
12 
10 
 
48 
66.7 
P 0.4119 (Not significant) 
 
 When the cut off value for LDL is taken as 100, it brings out 
statistically significant difference in BMI. 
   
Table 15 LDL (Taking 150 as cut off value) and other lipids 
 
LDL 
Normal Abnormal 
 
No % No % 
 
 
‘p’ 
F.C 
Normal 
Abnormal 
 
26 
6 
 
96.3 
46.2 
 
1 
7 
 
3.7 
53.8 
 
0.0009 
(Significant) 
TGL 
Normal  
Abnormal 
 
29 
3 
 
82.9 
60.0 
 
6 
2 
 
17.1 
40.0 
 
0.2568  
(Not significant) 
VLDL 
Normal 
Abnormal 
 
32 
2 
 
80 
- 
 
8 
- 
 
20 
- 
 
- 
HDL 
Normal 
Abnormal 
 
32 
- 
 
80 
- 
 
8 
- 
 
20 
- 
- 
 
   
Table 16 LDL (Taking 100 as cut off value) and other lipids 
 
LDL 
Normal Abnormal 
 
No % No % 
 
 
‘p’ 
F.C 
Normal 
Abnormal 
 
18 
- 
 
66.7 
- 
 
9 
13 
 
33.3 
100 
 
0.0003 
(Significant)
TGL 
Normal  
Abnormal 
 
18 
- 
 
51.4 
- 
 
17 
5 
 
48.6 
100 
 
0.04 
(Significant)
VLDL 
Normal 
Abnormal 
 
18 
- 
 
45.0 
- 
 
22 
- 
 
55 
- 
 
- 
- 
HDL 
Normal 
Abnormal 
 
18 
- 
 
45.0 
- 
 
22 
- 
 
55 
- 
 
- 
- 
 
 From Table 15 and Table 16, it is been that when 150 is taken as cut 
off level, significant abnormalities are observed only in free cholesterol, But 
when 100 is taken as cut off level for LDL, significant abnormalities are 
observed both in free cholesterol and TGL levels. 
 
 
 
 
 
 
   
 
 
 
 
 
DISCUSSION 
   
DISCUSSION 
 
 40 Kidney transplant patients attending the transplant OP, Nephrology 
Department were taken for the study. Among the 40 patients 33 were males 
and 7 were females. This study was undertaken between the period of 
1.8.2005 to 31.5.2006. Informed consent was obtained from all the patients 
before inclusion in this study. Apart from relevant medical history and 
physical examination including vitals, Anthropometry & Search for evidence 
of active infections and Graft rejection done. 
 
 A detailed history was taken with emphasis on socioeconomic status 
and dietary habits. Special consideration was given to findout prior diabetes 
mellitus (Type 1 or Type2), family history of premature CAD (male before 
the age of 55 years and females before the age of 65 years) and most probable 
cause of kidney failure. 
 
Details regarding mode of renal replacement therapy given and, nature 
of donor and compatibility postoperative complications including graft 
rejection episodes were recorded well. Current medical complications of the 
patients including hypertension, post transplant diabetes mellitus, (New onset 
diabetes mellitus), amount of weight gain, possible intercurrent infections 
were addressed. 
   
 Biochemical investigations like Renal Parameters, Urine Spot PCR, 
Fasting Lipid profile (12 hours fasting) and Plasma glucose were done for 
all of them.40 healthy volunteers attending medical OPD for minor ailments 
were taken as a control population. Biochemical investigations done after 12 
hours of overnight fasting. All specimens were analysed within 4 to 6 hours 
of collection. Laboratory procedure for lipid profile analysis included 
enzymatic method as well as estimation of LDL cholesterol by means of 
Friedewald formula. Apart from this, Fasting plasma glucose, Blood urea, 
Serum creatinine and Urine Spot protein creatinine ratio were done for all the 
patients. 
 
 Patients who were known Diabetes Mellitus, Nephrotic syndrome, 
Hypothyroidism, Liver disease, Clinical and/or Laboratory evidence of renal 
disease, active intercurrent infections, evidence of graft rejections and 
substance abuse (Smoking & Alcoholism) were excluded from the study. 
 
Comparative Analysis 
 In our study 40 patients including 33 males & 7 females were included. 
Lt Col KV Baliga et al study 15 patients including 12 males & 3 females were 
participated. 
 
 Majority of the patients in our study were in the age group of 26-46 
yrs. In KV. Baliga et al study it was between 26-44 yrs. 
   
 Most of our patients were males 82.5% (33) and remaining 17.5%(7) 
were females. In KV. Baliga et al males account for 80% (12) and females for 
remaining 20% (3). 
 
 In our study mean BMI was 23.1 + 2.5, whereas KV.Baliga et al study 
it was 21.4+ 1.1. So our study population were slightly heavier than KV. 
Baliga study population. 
 
In our study mean free cholesterol levels for patients with transplant 
duration of < 1yr and > 1yr were found to be 216 & 181mgr%. Corresponding 
figures in KV. Baliga study were 247 & 212mgr%. So our population had 
slightly lower values of free cholesterol irrespective of duration of 
transplant. In our study obese patients had mean free cholesterol of 
225mgr% & non obese had 183mgr%. This is statistically significant also 
mean free cholesterol levels for male and female in our study were 199 & 
171mgr% respectively. In KV. Baliga et al study these were 232 & 228mgr%. 
So our population had lower levels of free cholesterol compared to KV. 
Baliga et al study group. 
 
In our study mean TGL levels for patients with transplant duration of  
< 1yr and > 1yr were found to be 150 & 126 mgr%. Corresponding figures in 
KV. Baliga study were 173 & 139mgr%. So our population had slightly 
lower values of TGL irrespective of duration of transplant. In our study 
obese patients were found to be have higher TGL levels (148mgr %) 
   
compared to non obese patients (130mgr %). This one is statistically 
significant also. Mean TGL levels for male and female in our study were 135 
and 137mgr% respectively. In KV. Baliga et al study these were 158 and 
154mgr%. So our population had lower levels of TGL compared to KV. 
Baliga et al study group.  
 
In our study mean VLDL levels for patients with transplant duration of 
< 1year and > 1year were found to be 30 & 25mgr% obese patients had mean 
VLDL of 30mgr% and non obese patients had VLDL 26mgr%. This is 
statistically significant also. Mean VLDL levels (27mgr%) for male and 
female in our study were similar.  
 
In our study mean HDL levels for patients with transplant duration of  
< 1year and > 1year were found to be 50 & 47mgr%. Corresponding figures 
in KV. Baliga study were 45 & 53mgr%. In our study both obese patients and 
non obese patients had similar HDL levels (48mgr %). Mean HDL levels for 
male and female in our study were 49 & 44mgr% respectively. In KV. Baliga 
et al study these were 48 & 52mgr%. So our population had lower levels of 
HDL compared to KV. Baliga et al study group. 
 
 In our study mean LDL levels for patients with transplant duration of < 
1yr and > 1yr were found to be 142 & 109 mgr%. Corresponding figures in 
KV. Baliga study were 148 & 118 mgr%. So our population had slightly 
lower values of LDL irrespective of duration of transplant. In our study 
   
obese patients had mean LDL of 155 mgr% & non obese had 108 mgr%. So 
obese patients had very high LDL level compared to non – obese patients. 
This is statistically significant also. Mean LDL levels for male and female in 
our study were 123 & 114 mgr% respectively. Male patients had higher LDL 
level. In KV. Baliga et al study these were 139 & 130 mgr%. So our 
population had lower levels of LDL compared to KV. Baliga et al study 
group. 
 
 When applied the NKF recommendations for the LDL levels of < 100 
mg % as a therapeutic goal to our population, only 45% (18) of them were 
achieved goal LDL. Remaining 55% (22) had high LDL level of more than 
100 mg%. 
 
 Among the patients with abnormal LDL levels, most of them were 
found to be male (19) and remaining were females (3) in absolute numbers. 
Out of 33 male patients 24 were below the age of 40 years and remaining 9 
were above the age of 40 years. Out of 33 male patients 19 had abnormal 
LDL level (58%). Among the 19 male patients 12 were below the age of 40 
years (63%). Remaining 7 were above the age of 40 years (78%). 
 
 Out of 7 females 5 were below the age of 40 and 2 were above the age 
of 40. Out of 3 females one is below the age of 40 years (20%). Remaining 2 
were above the age of 40 years (100%).  
 
 So, abnormal LDL levels were seen more among above the age of 
40 years group.  
   
 
 
 
 
 
SUMMARY 
   
SUMMARY 
1. Most of the kidney transplant patients are below the age of 40 years. 
Age group ranges from 26 – 46 years. 29 out of 40 are below 40 years 
(72.5%). 
 
2. Male predominance is seen among the kidney transplant population. 
33 out of 40 (82.5%) of them are male. Most of the male patients had 
lipid profile abnormalities. 
 
3. Majority of the kidney transplant patients are non-obese as evidenced 
by BMI of less than 25. 29 out of 40 patients (72.5%) had BMI of less 
than 25. Remaining 27.5% are obese with BMI of more than 25. Most 
of the obese patients had abnormal lipid profile. 
 
4. 15 out of 40 patients are on triple drug regimen (Prednisolone, 
Azathioprine & Cyclosporine). Remaining 25 are on double drug 
regimen (Prednisolone, Azathioprine). 
 
5. Total cholesterol levels are within normal limits for 27 patients 
(67.5%). Remaining 13 (32.5%) had elevated total cholesterol. 
 
6. 35 out of 40 patients (87.5%) had normal triglyceride levels. 
Remaining 5 patients (12.5%) had elevated triglyceride levels. 
 
   
 
7. VLDL levels are normal for all 40 patients (100%). 
 
8. All patients had normal HDL cholesterol levels (100%). 
 
9. LDL cholesterol levels are normal for 32 patients (80%) if LDL cut off 
of more than 150 mg / dl is taken. If more than 100 mg / dl is taken as 
abnormal (NKF recommendation) then 22 patients (55 %) were not 
on the goal LDL level. 
 
10. Majority of patients on triple drug regimen were found to be having 
abnormal total cholesterol, triglyceride, VLDL, HDL and LDL. 
 
11. Majority of the patients above the age of 40 years had abnormal LDL 
levels irrespective of gender. 
 
12. Those on triple drug regimen (Prednisolone, Azathioprine & 
Cyclosporine) were found to be having abnormal levels of LDL. 
 
   
 
 
 
 
 
CONCLUSION 
   
CONCLUSION 
In our population, on applying NKF recommendations  
 
1. 55% of the patients had abnormal LDL levels. 
2. 58% of the males and 42% of females were found to be have 
abnormal LDL levels. 
3. Below the age of 40 years, 50% of the males and 20% of the 
females had abnormal LDL levels. 
4. Majority of the patients above the age of 40 years had 
abnormal LDL levels.(78% of the males and 100% of females). 
5. Majority of the patients on triple drug regimen (Prednsiolone, 
Azathioprine & Cylcosporine ) were found to be have abnormal 
LDL levels. 
 
In order to achieve therapeutic LDL level of < 100 mg% in our population, 
Therapeutic lifestyle change (TLC) should be the first measure. Even after 3 
months of adequate therapeutic lifestyle change (TLC), if LDL goals are not 
achieved statins should be started. Lowest effective dose of statin should be 
started and titrated accordingly. Frequent monitoring of liver function tests 
and creatinine phospho kinase is needed. 
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PROFORMA 
   
PROFORMA 
 
 
Name  :     Age   : 
 
Sex  :     Occupation : 
 
Address : 
 
 
History 
1. Probable cause of renal failure  
2.  Mode of renal replacement therapy given prior to transplant – HD / PD 
3. Nature of Donor – (Related / Unrelated / Cadaveric) & compatibility 
4. Post operative complications - including rejection 
5. Immunosuppressive drug regimen and amount of weight gain  
6. Prior Comorbid medical illness 
 
Clinical Examination 
1. Vital parameters 
2. Height, Weight, Body Mass Index 
3. Major systems examination 
4. Evidence of Active infections / graft rejection 
 
Biochemical Investigations 
1. 12 hours Fasting Lipid Profile  
 Free cholesterol 
 Triglycerides  
 HDL, LDL, VLDL 
2. Renal parameters (Blood Urea, Serum Creatinine) 
3. Fasting Plasma Glucose 
5. Urine spot protein creatinine ratio 
   
 
 
 
 
 
 
 
 
 
MASTER CHART 
   
MASTER CHART 
 
S.No GROUP 
AGE 
(years) 
Ht. 
(cm) BMI Wt(Kg)
FOLLOW 
UP REGIMEN Sex 
FC 
(mg%)
TG 
(mg%) 
HDL 
(mg%) 
LDL 
(mg%)
VLDL 
(mg%)
1 STUDY 27 156 23.8 58 15 2 1 180 100 35 125 20 
2 STUDY 34 160 22.7 58 15 2 1 160 100 50 90 20 
3 STUDY 38 160 23.4 60 18 2 1 150 100 45 85 20 
4 STUDY 29 154 27.0 64 8 3 1 240 180 40 164 36 
5 STUDY 31 158 24.0 60 18 2 1 160 110 45 93 22 
6 STUDY 34 160 19.5 50 16 2 1 170 150 45 95 30 
7 STUDY 36 156 23.8 58 10 3 1 230 180 50 144 36 
8 STUDY 34 156 22.2 54 14 2 1 190 130 40 124 26 
9 STUDY 40 158 24.0 60 8 3 1 230 150 40 160 30 
10 STUDY 34 154 22.8 54 16 2 1 160 100 50 90 20 
11 STUDY 26 156 25.5 62 14 2 1 190 100 50 120 20 
12 STUDY 28 158 25.6 64 6 3 1 280 150 50 200 30 
13 STUDY 33 154 26.1 62 8 3 1 250 150 50 170 30 
14 STUDY 36 160 21.9 56 18 2 2 150 110 40 88 22 
15 STUDY 28 154 21.9 52 18 2 2 160 120 50 86 24 
16 STUDY 32 156 22.2 54 10 3 2 230 180 50 144 36 
17 STUDY 38 152 26.0 60 14 2 2 180 120 30 126 24 
18 STUDY 42 156 25.5 62 9 3 2 150 180 40 174 36 
19 STUDY 40 156 20.5 50 15 2 2 160 120 50 86 22 
20 STUDY 46 158 18.4 46 10 3 2 170 130 50 94 26 
21 STUDY 33 156 21.4 52 11 3 1 180 120 60 96 24 
22 STUDY 29 158 19.2 48 10 3 1 180 120 55 91 24 
23 STUDY 32 160 23.4 60 14 2 1 230 170 50 146 34 
24 STUDY 42 158 19.2 48 7 3 1 160 130 40 94 26 
25 STUDY 44 156 20.5 50 17 2 1 160 140 45 87 28 
26 STUDY 35 150 25.8 58 14 2 1 240 150 60 150 30 
27 STUDY 39 160 19.5 50 15 2 1 180 130 60 94 26 
28 STUDY 31 156 23.0 56 14 2 1 220 150 50 140 30 
29 STUDY 40 160 24.2 62 15 2 1 200 140 40 132 28 
30 STUDY 41 164 23.8 64 8 3 1 240 150 40 170 30 
31 STUDY 46 158 25.6 64 15 2 1 200 150 50 120 30 
   
S.No GROUP 
AGE 
(years) 
Ht. 
(cm) BMI Wt(Kg)
FOLLOW 
UP REGIMEN Sex 
FC 
(mg%)
TG 
(mg%) 
HDL 
(mg%) 
LDL 
(mg%)
VLDL 
(mg%)
32 STUDY 44 152 28.6 66 14 2 1 220 150 40 150 30 
33 STUDY 37 164 21.6 58 15 2 1 170 140 50 92 28 
34 STUDY 44 150 26.7 60 8 3 1 250 150 60 160 30 
35 STUDY 29 164 21.6 58 18 2 1 180 140 60 92 28 
36 STUDY 45 156 25.5 62 8 3 1 270 150 60 180 30 
37 STUDY 33 180 18.5 60 8 3 1 180 130 60 94 26 
38 STUDY 45 160 22.7 58 14 2 1 190 130 40 126 26 
39 STUDY 44 150 24.9 56 16 2 1 180 120 40 116 24 
40 STUDY 36 170 20.1 58 18 2 1 160 100 60 80 20 
41 CONTROL 29 156 23.8 58   1 170 130 50 94 26 
42 CONTROL 32 160 21.9 56   1 180 120 60 96 24 
43 CONTROL 34 158 21.6 54   1 140 90 40 82 18 
44 CONTROL 34 160 21.1 54   1 150 100 50 80 20 
45 CONTROL 30 152 24.2 56   1 160 100 50 90 20 
46 CONTROL 28 156 23.0 56   1 190 150 60 100 30 
47 CONTROL 44 156 23.8 58   1 200 140 50 122 28 
48 CONTROL 40 158 24.0 60   1 260 210 50 168 42 
49 CONTROL 26 156 26.3 64   1 180 100 60 100 20 
50 CONTROL 42 152 26.0 60   1 195 120 40 131 24 
51 CONTROL 46 158 24.8 62   1 200 150 40 130 30 
52 CONTROL 43 154 26.1 62   1 160 100 40 100 20 
53 CONTROL 28 156 23.8 58   1 170 120 60 86 24 
54 CONTROL 34 154 21.1 50   1 180 120 60 96 24 
55 CONTROL 38 156 22.2 54   1 180 150 40 110 30 
56 CONTROL 28 160 22.7 58   1 190 150 60 100 30 
57 CONTROL 42 150 22.2 50   1 190 140 40 122 28 
58 CONTROL 27 160 21.1 54   1 180 130 60 94 30 
59 CONTROL 34 158 25.6 64   1 170 120 50 96 24 
60 CONTROL 36 156 21.4 52   1 160 120 50 84 24 
61 CONTROL 28 160 25.8 66   2 170 110 60 88 22 
62 CONTROL 31 156 22.2 54   2 170 120 50 96 24 
63 CONTROL 39 172 20.3 60   2 160 110 60 78 22 
64 CONTROL 36 170 19.4 56   2 150 100 50 80 20 
   
S.No GROUP 
AGE 
(years) 
Ht. 
(cm) BMI Wt(Kg)
FOLLOW 
UP REGIMEN Sex 
FC 
(mg%)
TG 
(mg%) 
HDL 
(mg%) 
LDL 
(mg%)
VLDL 
(mg%)
65 CONTROL 45 156 26.3 64   2 240 200 50 150 40 
66 CONTROL 37 168 21.3 60   2 150 100 40 90 20 
67 CONTROL 35 170 20.8 60   2 160 100 50 90 20 
68 CONTROL 43 154 26.1 62   2 250 200 60 150 40 
69 CONTROL 33 160 22.7 58   2 170 100 50 100 20 
70 CONTROL 45 158 24.8 62   2 180 110 60 98 22 
71 CONTROL 32 154 27.0 64   1 160 100 50 110 20 
72 CONTROL 27 152 26.0 60   1 170 100 50 100 20 
73 CONTROL 25 164 20.8 56   1 150 100 60 70 20 
74 CONTROL 44 150 23.1 52   1 220 150 60 130 30 
75 CONTROL 26 162 22.1 58   1 160 100 60 80 20 
76 CONTROL 44 164 22.3 60   1 170 110 60 88 22 
77 CONTROL 27 156 24.7 60   1 230 150 60 140 30 
78 CONTROL 31 162 22.1 58   1 170 120 50 96 24 
79 CONTROL 34 160 24.2 62   1 170 120 60 86 24 
80 CONTROL 29 158 25.6 64   1 160 120 50 86 24 
 
 
Sex  1 - Male 
  2 - Female 
 
Regimen 3 - Triple Drug 
  2 - Double drug 
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LDL (Taking 150 as cut off value) and other lipids
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LDL (Taking 100 as cut off value) and other lipids
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